1. Medtech Insight
  2. >>Archive

AF Ablation: Progress & Promise

Tremendous progress has been made in the field of ablation therapy for atrial fibrillation (AF) over the past several years, and numerous device-based technologies to address this underserved and rapidly growing patient population are under clinical development. Minimally invasive, percutaneous AF ablation has evolved rapidly as well, although the procedure remains very challenging and limited to highly experienced centers.

Tremendous progress has been made in the field of ablation therapy for atrial fibrillation (AF) over the past several years, and numerous device-based technologies to address this underserved and rapidly growing patient population are under clinical development. Perhaps most exciting is the area of percutaneous AF ablation, which has evolved from a highly experimental therapy only a few years ago to what many leading electrophysiologists (EPs) now consider a mainstream treatment option for certain patients. But while there is no doubt that the number of catheter-based AF ablations is on the rise, the procedure remains very challenging and limited, for the most part, to highly experienced centers. The question now is whether technological advances and expanding clinical experience will enable percutaneous ablation to move from the hands of a select few EPs treating a carefully selected patient population into wider use.

Cardiac surgeons also are eager to offer treatment for the underserved AF population, and device manufacturers are aggressively targeting this space as well, seeking to expand AF surgical options from highly invasive concomitant procedures—performed in conjunction with open-heart cardiac bypass or heart valve

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

23andMe Purchase Will Let Regeneron Scale Drug Development

 
• By Alaric DeArment

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

Disparities — Including Financials Shortcomings — Remain In Women’s Health, Execs Say

 
• By Brian Bossetta

FemTech leaders discussed some of the barriers that remain in unlocking the full potential of the women’s health market during SiS New York last week. They also offered solutions.

Mirvie Launches Predictive Blood Test For Preeclampsia

 
• By Marion Webb

Mirvie launched Encompass, a blood test to help identify women over age 35 who are at moderate risk for preeclampsia, and will conduct additional studies to support reimbursements from payers.